Abstract
BackgroundAlmost all assisted reproductive technology (ART) and intrauterine insemination (IUI) treatments performed in Australia are subsidized through the Australian Government’s universal insurance scheme, Medicare. In 2010 restrictions on the amount Medicare paid in benefits for these treatments were introduced, increasing patient out-of-pocket payments for fresh and frozen embryo ART cycles and IUI. The aim of this study was to evaluate the impact of the policy on access to treatment, savings in Medicare benefits and the number of ART conceived children not born.MethodsPooled quarterly cross-sectional Medicare data from 2007 and 2011 where used to construct a series of Ordinary Least Squares (OLS) regression models to evaluate the impact of the policy on access to treatment by women of different ages. Government savings in the 12 months after the policy was calculated as the difference between the predicted and observed Medicare benefits paid.ResultsAfter controlling for underlying time trends and unobserved factors the policy change reduced the number of fresh embryo cycles by almost 8600 cycles over 12 months (a 16% reduction in cycles, p < 0.001). The policy effect was greatest on women aged 40 years and older (38% reduction in cycles, p < 0.001). Younger women engaged in relatively more anticipatory behaviour by bringing forward their fresh cycles to 2009. Frozen embryo cycles, which are approximately one quarter of the cost of a fresh cycle, were only marginally impacted by the policy. Utilisation of IUI cycles were not impacted by the policy. After adjusting for anticipatory behaviour, $76 million in Medicare benefits was saved in the 12 months after the policy change (0.47% of annual Medicare benefits). Between 1200 and 1500 ART conceived children were not born in 2010 as a consequence of the policy.ConclusionsThe introduction of the policy resulted in a significant reduction in fresh ART cycles in the first 15 months after its introduction. Further evaluation on the long term impact of the policy with regard access to treatment and on clinical practice, particularly the number of embryos transferred, is crucial to ensuring equitable access to fertility treatment and the health and welfare of ART children.
Highlights
Almost all assisted reproductive technology (ART) and intrauterine insemination (IUI) treatments performed in Australia are subsidized through the Australian Government’s universal insurance scheme, Medicare
Descriptive statistics Age specific groups, provider fees, Medicare benefits and out-of-pocket costs Prior to the introduction of the Extended Medicare Safety Net Cap (EMSNCap) there was an annual increase in Fresh Cycles of +12% and +17% in 2008 and 2009 respectively
Compared with Fresh Cycles, the annual increase in Frozen Cycles before the EMSNCaps followed by the decrease after the policy was less pronounced
Summary
Almost all assisted reproductive technology (ART) and intrauterine insemination (IUI) treatments performed in Australia are subsidized through the Australian Government’s universal insurance scheme, Medicare. Over 72 million women worldwide are currently produce multiple mature eggs, removal of the mature eggs under anaesthesia, fertilisation of the eggs outside of the body to create embryos, and the transfer of one or more 26 day-old embryos back into the woman’s uterus This type of ART cycle is termed a fresh embryo transfer cycle (Fresh Cycle). Along with ARTs the most common form of medical intervention to treat infertility is intrauterine inseminaton (IUI), whereby sperm - a partner’s or donor’s - is deposited directly into a woman’s uterus to aid conception This can be either performed in a treatment cycle where the ovaries have been stimulated with hormones to mature multiple eggs or in an unstimulated cycle
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
